Healthcare entity
All 1 tracked stories fall under one category: market-trends. Of the tracked stories, 1 of 1 also mention David Soergel, the most common co-covered peer. Each story carries 5 original sources on average, compared with 2.4 for the broader beat in this window.
Last mentioned: Feb 24, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: market-trends. Of the tracked stories, 1 of 1 also mention David Soergel, the most common co-covered peer. Each story carries 5 original sources on average, compared with 2.4 for the broader beat in this window. Their average consequence score of 7 runs above the beat's 6 for that window. We currently track 1 Healthcare story that mention Mardi C. Dier, all published on February 24, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 26 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Mardi C. Dier. Shared-story counts are live from our verified record — not editorial picks.
Payer Agreement Shift
New payer contracts take effect, shifting GTN expectations to the high 30% range for the fiscal year.
Q4 Milestone
Patient count surpasses 36,000 and quarterly revenue exceeds $320 million.
GLP-1 Strategic Acquisition
Madrigal makes a $120 million upfront payment for an oral GLP-1 asset to expand its metabolic pipeline.
Rezdiffra Full-Year Launch
Madrigal begins its first full year of commercial sales for the first-ever approved MASH treatment.
Madrigal Pharmaceuticals reported a transformative Q4 2025, with Rezdiffra net sales reaching $321.1 million and a patient base exceeding 36,000. The company is aggressively expanding its metabolic pipeline, integrating GLP-1 and siRNA technologies to solidify its leadership in the MASH market.
Source: Motley Fool Transcribing (us) · Motley Fool Transcribing (us)
Mardi C. Dier is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
